These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 37081729)
21. A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer. Okuma Y; Hosomi Y; Takahashi S; Nakahara Y; Watanabe K; Nagamata M; Takagi Y; Mikura S Cancer Chemother Pharmacol; 2016 Aug; 78(2):383-8. PubMed ID: 27339149 [TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of nanoparticle albumin-bound paclitaxel in taxane-pretreated metastatic breast cancer patients. Xiong W; Xu T; Liu X; Zhang L; Yuan Y Cancer; 2024 Apr; 130(S8):1488-1498. PubMed ID: 38271397 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial. Kogure Y; Iwasawa S; Saka H; Hamamoto Y; Kada A; Hashimoto H; Atagi S; Takiguchi Y; Ebi N; Inoue A; Kurata T; Okamoto I; Yamaguchi M; Harada T; Seike M; Ando M; Saito AM; Kubota K; Takenoyama M; Seto T; Yamamoto N; Gemma A Lancet Healthy Longev; 2021 Dec; 2(12):e791-e800. PubMed ID: 36098037 [TBL] [Abstract][Full Text] [Related]
25. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis. Tan H; Hu J; Liu S Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):268-277. PubMed ID: 30600739 [TBL] [Abstract][Full Text] [Related]
27. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302). Tamura S; Taniguchi H; Nishikawa K; Imamura H; Fujita J; Takeno A; Matsuyama J; Kimura Y; Kawada J; Hirao M; Hirota M; Fujitani K; Kurokawa Y; Sakai D; Kawakami H; Shimokawa T; Satoh T Int J Clin Oncol; 2020 Dec; 25(12):2035-2043. PubMed ID: 32926227 [TBL] [Abstract][Full Text] [Related]
28. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164 [TBL] [Abstract][Full Text] [Related]
29. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease. Kenmotsu H; Yoh K; Mori K; Ono A; Baba T; Fujiwara Y; Yamaguchi O; Ko R; Okamoto H; Yamamoto N; Ninomiya T; Ogura T; Kato T Cancer Sci; 2019 Dec; 110(12):3738-3745. PubMed ID: 31608537 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Satouchi M; Okamoto I; Sakai H; Yamamoto N; Ichinose Y; Ohmatsu H; Nogami N; Takeda K; Mitsudomi T; Kasahara K; Negoro S Lung Cancer; 2013 Jul; 81(1):97-101. PubMed ID: 23545279 [TBL] [Abstract][Full Text] [Related]
31. Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy. Weiss JM; Pennell N; Deal AM; Morgensztern D; Bradford DS; Crane J; West HJ; Lee C; Pecot C; Stevenson JP; Irvin W; Socinski M; Stinchcombe T; Villaruz LC; Muss HB Cancer; 2020 Mar; 126(5):1060-1067. PubMed ID: 31943168 [TBL] [Abstract][Full Text] [Related]
32. A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Hattori Y; Kono Y; Itoh S; Inoue T; Urata Y; Kawa Y; Tohnai R; Kumagai T; Nishino K; Uozumi R; Morita S; Negoro S; Imamura F; Satouchi M BMC Cancer; 2020 Feb; 20(1):115. PubMed ID: 32046667 [TBL] [Abstract][Full Text] [Related]
33. A phase II feasibility study of carboplatin and nab-paclitaxel for advanced non-small cell lung cancer patients with interstitial lung disease (YLOG0114). Sakashita H; Uchibori K; Jin Y; Tsutsui T; Honda T; Sakakibara R; Mitsumura T; Nukui Y; Shirai T; Masuo M; Suhara K; Furusawa H; Yamashita T; Ohba T; Saito K; Takagiwa J; Miyashita Y; Inase N; Miyazaki Y Thorac Cancer; 2022 May; 13(9):1267-1275. PubMed ID: 35322551 [TBL] [Abstract][Full Text] [Related]
34. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma. Jin F; Zhu H; Shi F; Kong L; Yu J Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611 [TBL] [Abstract][Full Text] [Related]
35. Stromal Caveolin-1 Is Associated With Response and Survival in a Phase II Trial of nab-Paclitaxel With Carboplatin for Advanced NSCLC Patients. Bertino EM; Williams TM; Nana-Sinkam SP; Shilo K; Chatterjee M; Mo X; Rahmani M; Phillips GS; Villalona-Calero MA; Otterson GA Clin Lung Cancer; 2015 Nov; 16(6):466-74. PubMed ID: 26123189 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of PD-1 Immune Checkpoint Inhibitors in Locally Advanced and Advanced Non-Small-Cell Lung Cancer Patients with Chronic Infection. Zhao Z; Hu R; Chen Y; Zhou G; Yu S; Feng J Oncol Res Treat; 2022; 45(6):366-374. PubMed ID: 35231913 [TBL] [Abstract][Full Text] [Related]
37. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial. Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053 [TBL] [Abstract][Full Text] [Related]
38. Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial. Wang J; Lu S; Yu X; Hu Y; Sun Y; Wang Z; Zhao J; Yu Y; Hu C; Yang K; Feng G; Ying K; Zhuang W; Zhou J; Wu J; Leaw SJ; Zhang J; Lin X; Liang L; Yang N JAMA Oncol; 2021 May; 7(5):709-717. PubMed ID: 33792623 [TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of weekly intravenous nanoparticle albumin-bound paclitaxel for non-small cell lung cancer patients who have failed at least two prior systemic treatments. Duan J; Hao Y; Wan R; Yu S; Bai H; An T; Zhao J; Wang Z; Zhuo M; Wang J Thorac Cancer; 2017 May; 8(3):138-146. PubMed ID: 28304139 [TBL] [Abstract][Full Text] [Related]
40. A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer. Tanaka H; Taima K; Morimoto T; Tanaka Y; Itoga M; Nakamura K; Hayashi A; Kumagai M; Yasugahira H; Mikuniya M; Okudera K; Takanashi S; Tasaka S BMC Cancer; 2017 Oct; 17(1):683. PubMed ID: 29037236 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]